{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:08:38Z","timestamp":1760486918066,"version":"build-2065373602"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T00:00:00Z","timestamp":1747526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"French Medicines Agency"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The COVID-19 pandemic disrupted healthcare access, potentially impacting cardiovascular prevention by increasing and worsening interruptions in antihypertensive treatment. In this context, we aimed to assess whether the epidemic had modified the effect of antihypertensive interruptions on the risk of major cardiovascular events (MACE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From the nationwide SNDS French health insurance databases (2018\/01\/01-2021\/12\/31), we identified patients with \u22651 year of continuous antihypertensive drug use. We then constituted a group of patients who interrupted an antihypertensive during the period (interrupters) i.e., who presented with a treatment gap for at least one antihypertensive (entry date: interruption date). Interruption length defined was defined as time to treatment restart. After 1:1 matching, we constituted a second group of patients with continuous antihypertensive treatment at interrupters entry date (persisters; entry date: interrupter entry date). Associations between MACE risk, antihypertensive drug interruption (all durations, \u226515 days, \u226530 days), COVID epidemic period, and the interaction between these were assessed using GEE multivariable models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 2,072,672 interrupter\/persister pairs were included (4,145,344 patients; 43.6% in COVID period). Risk of MACE was not found increased after interruptions overall (OR\u2005=\u20050.99; 95%CI [0.97\u20131.02]); it was when interruptions lasted at least fifteen days (OR\u2005=\u20051.03 [1.01\u20131.06]) and during the COVID period independently of the existence of interruptions (OR\u2005=\u20051.44 [1.39\u20131.50]; P-value for interaction: all interruptions 0.69, exceeding 15 days 0.65).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The COVID epidemic period was associated with an increased risk of MACE or all-cause death in antihypertensive drug users without worsening the effect of antihypertensive drug interruptions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpaf085","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T14:19:32Z","timestamp":1747577972000},"page":"924-931","source":"Crossref","is-referenced-by-count":0,"title":["Effect of the COVID-19 Epidemic on the Association Between Antihypertensive Drug Interruption and the Risk of Major Cardiovascular Event in France"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3615-148X","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Mathieu","sequence":"first","affiliation":[{"name":"Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, AHeaD team , UMR 1219, Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, AHeaD team , UMR 1219, Bordeaux ,","place":["France"]},{"name":"CHU de Bordeaux, P\u00f4le de sant\u00e9 publique, Service de pharmacologie , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7873-5483","authenticated-orcid":false,"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, AHeaD team , UMR 1219, Bordeaux ,","place":["France"]},{"name":"CHU de Bordeaux, P\u00f4le de sant\u00e9 publique, Service de pharmacologie , Bordeaux ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,18]]},"reference":[{"key":"2025101319565872000_CIT0001","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3390\/jpm12081295","article-title":"Global challenges to public health care systems during the COVID-19 pandemic: a review of pandemic measures and problems","volume":"12","author":"Filip","year":"2022","journal-title":"J Pers Med"},{"key":"2025101319565872000_CIT0002","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S0140-6736(22)01585-9","article-title":"The Lancet Commission on lessons for the future from the COVID-19 pandemic","volume":"400","author":"Sachs","year":"2022","journal-title":"The Lancet"},{"key":"2025101319565872000_CIT0003","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10654-022-00912-2","article-title":"Impact of the COVID-19 pandemic and its control measures on cardiovascular and antidiabetic drugs use in France in 2020: a nationwide repeated cohort study","volume":"37","author":"Mathieu","year":"2022","journal-title":"Eur J Epidemiol"},{"key":"2025101319565872000_CIT0004","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1097\/01.hjh.0000939504.83761.e5","article-title":"Use of antihypertensive combination therapy during the COVID-19 pandemic - a cross-sectional, nation-wide study 2019-2021","volume":"41","author":"Dobrowolski","year":"2023","journal-title":"J Hypertens"},{"key":"2025101319565872000_CIT0005","doi-asserted-by":"publisher","first-page":"1129244","DOI":"10.3389\/fphar.2023.1129244","article-title":"Impact of COVID-19 epidemic on antihypertensive drug treatment disruptions: results from a nationwide interrupted time-series analysis","volume":"14","author":"Mathieu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025101319565872000_CIT0006","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1185\/030079908x253843","article-title":"The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke","volume":"24","author":"Breekveldt-Postma","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2025101319565872000_CIT0007","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/jhh.2017.1","article-title":"Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study","volume":"31","author":"Alharbi","year":"2017","journal-title":"J Hum Hypertens"},{"key":"2025101319565872000_CIT0008","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1097\/HJH.0000000000001405","article-title":"Withdrawal of antihypertensive medication: a systematic review","volume":"35","author":"van der Wardt","year":"2017","journal-title":"J Hypertens"},{"key":"2025101319565872000_CIT0009","doi-asserted-by":"publisher","first-page":"CD011971","DOI":"10.1002\/14651858.CD011971.pub2","article-title":"Antihypertensive withdrawal for the prevention of cognitive decline","volume":"2016","author":"Jongstra","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025101319565872000_CIT0010","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/eurheartj\/ehaa409","article-title":"Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era","volume":"41","author":"De Rosa","year":"2020","journal-title":"Eur Heart J"},{"key":"2025101319565872000_CIT0011","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/eurheartj\/ehaa314","article-title":"Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage","volume":"41","author":"Metzler","year":"2020","journal-title":"Eur Heart J"},{"key":"2025101319565872000_CIT0012","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(20)31356-8","article-title":"COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England","volume":"396","author":"Mafham","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2025101319565872000_CIT0013","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/ehjqcco\/qcaa049","article-title":"Emergency hospital admissions and interventional treatments for heart failure and cardiac arrhythmias in Germany during the Covid-19 outbreak: insights from the German-wide Helios hospital network","volume":"6","author":"Bollmann","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2025101319565872000_CIT0014","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1056\/NEJMc2015630","article-title":"The Covid-19 pandemic and the incidence of acute myocardial infarction","volume":"383","author":"Solomon","year":"2020","journal-title":"N Engl J Med"},{"key":"2025101319565872000_CIT0015","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1016\/S2468-2667(20)30117-1","article-title":"Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a population-based, observational study","volume":"5","author":"Marijon","year":"2020","journal-title":"Lancet Public Health"},{"key":"2025101319565872000_CIT0016","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc2010418","article-title":"Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy","volume":"383","author":"Baldi","year":"2020","journal-title":"N Engl J Med"},{"key":"2025101319565872000_CIT0017","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2025101319565872000_CIT0018","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2025101319565872000_CIT0019","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2025101319565872000_CIT0020","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025101319565872000_CIT0021","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/pds.5366","article-title":"Pharmacological and epidemiological considerations while constructing treatment episodes using observational data: a simulation study","volume":"31","author":"Pazzagli","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025101319565872000_CIT0022","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"volume-title":"Epid\u00e9miologie de terrain (2e \u00e9dition): M\u00e9thodes et applications","year":"2017","author":"Dabis","key":"2025101319565872000_CIT0023"},{"key":"2025101319565872000_CIT0024","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.therap.2019.10.001","article-title":"Polypharmacy: a general review of definitions, descriptions and determinants","volume":"75","author":"Guillot","year":"2020","journal-title":"Therapie"},{"key":"2025101319565872000_CIT0025","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD012572.pub2","article-title":"Withdrawal of antihypertensive drugs in older people","volume":"1","author":"Reeve","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025101319565872000_CIT0026","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/ajh\/hpad027","article-title":"Discontinuation of renin-angiotensin system inhibitors during the early stage of the COVID-19 pandemic","volume":"36","author":"Muntner","year":"2023","journal-title":"Am J Hypertens"},{"key":"2025101319565872000_CIT0027","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1161\/HYPERTENSIONAHA.116.07982","article-title":"Continuing or temporarily stopping prestroke antihypertensive medication in acute stroke","volume":"69","author":"Woodhouse","year":"2017","journal-title":"Hypertension"},{"key":"2025101319565872000_CIT0028","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1474-4422(15)00200-8","article-title":"The effects of socioeconomic status on stroke risk and outcomes","volume":"14","author":"Marshall","year":"2015","journal-title":"Lancet Neurol"},{"key":"2025101319565872000_CIT0029","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/eurheartj\/ehr045","article-title":"Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure","volume":"32","author":"Redon","year":"2011","journal-title":"Eur Heart J"},{"key":"2025101319565872000_CIT0030","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/01.STR.25.1.40","article-title":"Stroke risk profile: adjustment for antihypertensive medication. The Framingham study","volume":"25","author":"D\u2019Agostino","year":"1994","journal-title":"Stroke"},{"key":"2025101319565872000_CIT0031","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"2003 European Society of Hypertension\u2013European Society of Cardiology guidelines for the management of arterial hypertension*","volume":"21","author":"Committee","year":"2003","journal-title":"J Hypertens"},{"key":"2025101319565872000_CIT0032","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0140-6736(21)00896-5","article-title":"Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study","volume":"398","author":"Katsoularis","year":"2021","journal-title":"Lancet (London, England)"},{"key":"2025101319565872000_CIT0033","doi-asserted-by":"publisher","first-page":"o1838","DOI":"10.1136\/bmj.o1838","article-title":"Covid-19: Infection raises risk of diabetes and heart disease diagnoses in following weeks, study finds","volume":"378","author":"Wise","year":"2022","journal-title":"BMJ"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaf085\/63218218\/hpaf085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/11\/924\/63218218\/hpaf085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/38\/11\/924\/63218218\/hpaf085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T23:57:36Z","timestamp":1760399856000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/38\/11\/924\/8134364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,18]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,5,18]]},"published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaf085","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"type":"print","value":"0895-7061"},{"type":"electronic","value":"1941-7225"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,5,18]]}}}